Seres Therapeutics (MCRB) PT Lowered to $7 at Goldman Sachs

March 9, 2018 6:45 AM

Goldman Sachs lowered its price target on Seres Therapeutics (NASDAQ: MCRB) to $7.00 (from $8.00) while maintaining a Neutral rating.

No results found